McKesson vs Medline
McKesson is the larger business, with $403.43bn of revenue in fiscal 2026 against $28.43bn for Medline (14.2 times as much). McKesson grew faster (12.4% against 11.5%). Medline kept more of each dollar of sales as profit: a net margin of 4.1% against 1.2%.
| Latest fiscal year | McKessonMCK, 2026 | MedlineMDLN, 2025 |
|---|---|---|
| Revenue | $403.43bn | $28.43bn |
| Revenue growth | 12.4% | 11.5% |
| Net income | $4.76bn | $1.15bn |
| Operating margin | 1.5% | 7.8% |
| Net margin | 1.2% | 4.1% |
| Return on equity | — | 10.7% |
| Free cash flow | $5.72bn | $1.30bn |
| Cash | $3.98bn | $1.94bn |
| Total debt | $6.53bn | $12.76bn |
| Debt to equity | — | 118.8% |
| Dividend per share | $3.17 | — |
| Dividend yield | 0.3% | — |
| Share buybacks | $4.75bn | $33.0m |
| Employees | 43,000 | 45,000 |
| Market value | $119.67bn | $27.62bn |
| Price vs our value range | Within our value range | — |
| Moat score | 43 (Weak) | — |
| Insider trades, 12 months | 0 buys, 19 sales | 5 buys, 41 sales |